NEW YORK, August 28, 2023 -- Pfizer Inc. (NYSE: PFE) provides an update regarding its ongoing efforts to recover from a destructive tornado that damaged predominantly the warehouse portion of its Rocky Mount manufacturing facility on July 19.

Site Operations:
- The site reopened on August 7 and current efforts to restart production are on track and the following areas in the facility are now operational:
  - Quality laboratories and processes, including Incoming Materials, Chemical, and Biological Quality
  - Product Finishing (Packaging) and Inspection Operations
  - Supply Chain and Warehouse
  - Other support functions
- To accommodate product storage, a temporary warehouse location has been secured and a certificate of occupancy has been issued.

Supply of Medicines:
- Pfizer is working diligently to release any product that may not have been impacted and passes quality assessments.
- Pfizer has started releasing to distribution centers units of product that was not impacted by the tornado. This product was cleared for release through our stringent quality assurance processes.
- In addition to the work done to resume production, Pfizer is also working on knowledge and documentation transfers for product manufacturing (tech transfers) to other sterile injectable sites in the network to accelerate the supply of its products. This includes working with regulatory bodies to ensure compliance and to obtain approvals.
- These are important steps in Pfizer’s commitment to recover swiftly from this natural disaster and provide critical sterile injectable products to patients.
- There are many sequential steps and variables to restart operations and Pfizer is making significant progress. Pfizer anticipates production to restart by Q4 2023.

Future updates will be provided as new information becomes available.

Pfizer and its colleagues are working closely with the U.S. Food and Drug Administration, other regulatory bodies and state and local officials on restoring the Rocky Mount facility to full operations and ensuring that there is minimum disruption to the supply of medicines as possible.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE:
The information contained in this release is as of August 29th, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s ongoing efforts to recover from the damage caused by a tornado to Pfizer’s Rocky Mount, North Carolina manufacturing facility that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to complete repairs to the facility, replacing damaged raw material and supplies and restoring full function to the site in the anticipated timeframe or at all; other business effects, including the effects of industry, market, economic, political or regulatory conditions; uncertainties regarding the impact of COVID-19; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

###